Elicio Therapeutics, Inc. (ELTX)Healthcare | Biotechnology | Boston, United States | NasdaqCM
13.55 USD
+0.95
(7.540%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 13.28 -0.27 (-0.270%) ⇩ (April 17, 2026, 6:39 p.m. EDT) Short-term: ★★★★☆ | Long-term: ☆☆☆☆☆ | Dividends: ★☆☆☆☆ |
Hot Take | April 19, 2026, 12:10 a.m. EDT
ELTX presents a paradox: a technical bottom forming with positive analyst sentiment, but zero fundamental substance. The price has risen nearly 35% recently on a mere 5% four-year dividend yield. The bullish call rating is based entirely on short-term momentum recovery and analyst upgrades, not earnings or asset value. Long-term investors should view the 'Strong Buy' recommendations with extreme caution given the negative EPS and infinite P/E ratio; the stock is purely a speculative momentum play resting in a liquidity desert. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.219078 |
| AutoTheta | 0.219855 |
| AutoARIMA | 0.232287 |
| AutoETS | 0.232289 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 27.89 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.214 |
| Excess Kurtosis | -1.28 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 887.042 |
| Market Cap | 249,266,800 |
| Forward P/E | -7.66 |
| Beta | 1.88 |
| Previous Name | Angion Biomedica Corp. |
| Website | https://elicio.com |
As of April 19, 2026, 12:10 a.m. EDT: Options data exhibits extremely low implied volatility (1.0–2.6%) and negligible Open Interest, indicating a near-total absence of institutional or retail expectations. Short calls and puts show no concentrated strikes, with volume consistently lower than OI, signifying a lack of directional conviction. The primary signal is speculative: speculators are not positioning for a crash or a breakout, effectively 'hiking' on the stock until catalysts emerge.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.8229167 |
| Address1 | 451 D Street |
| Address2 | 5th Floor Suite 501 |
| All Time High | 263.0 |
| All Time Low | 2.96 |
| Ask | 13.49 |
| Ask Size | 1 |
| Audit Risk | 10 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 144,160 |
| Average Daily Volume3 Month | 140,854 |
| Average Volume | 140,854 |
| Average Volume10Days | 144,160 |
| Beta | 1.882 |
| Bid | 12.73 |
| Bid Size | 1 |
| Board Risk | 6 |
| Book Value | 0.092 |
| City | Boston |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 13.55 |
| Current Ratio | 2.381 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 13.89 |
| Day Low | 12.6 |
| Debt To Equity | 887.042 |
| Display Name | Elicio Therapeutics |
| Earnings Timestamp End | 1,755,288,000 |
| Earnings Timestamp Start | 1,754,942,400 |
| Ebitda | -37,510,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.537 |
| Enterprise Value | 245,215,808 |
| Eps Current Year | -1.95 |
| Eps Forward | -1.77 |
| Eps Trailing Twelve Months | -2.58 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 10.747 |
| Fifty Day Average Change | 2.8030005 |
| Fifty Day Average Change Percent | 0.26081702 |
| Fifty Two Week Change Percent | 182.29167 |
| Fifty Two Week High | 14.93 |
| Fifty Two Week High Change | -1.3800001 |
| Fifty Two Week High Change Percent | -0.09243135 |
| Fifty Two Week Low | 4.695 |
| Fifty Two Week Low Change | 8.855 |
| Fifty Two Week Low Change Percent | 1.8860488 |
| Fifty Two Week Range | 4.695 - 14.93 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,612,535,400,000 |
| Float Shares | 12,712,239 |
| Forward Eps | -1.77 |
| Forward P E | -7.6553674 |
| Free Cashflow | -21,666,376 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 33 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.30879998 |
| Held Percent Institutions | 0.1393 |
| Implied Shares Outstanding | 18,396,074 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,685,664,000 |
| Last Split Factor | 1:10 |
| Long Business Summary | Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts. |
| Long Name | Elicio Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 249,266,800 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_214936128 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-19 |
| Net Income To Common | -39,571,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 248,071,057 |
| Number Of Analyst Opinions | 3 |
| Open | 12.6 |
| Operating Cashflow | -36,952,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 857 209 0050 |
| Post Market Change | -0.27000046 |
| Post Market Change Percent | -1.9926233 |
| Post Market Price | 13.28 |
| Post Market Time | 1,776,465,588 |
| Prev Name | Angion Biomedica Corp. |
| Previous Close | 12.6 |
| Price Eps Current Year | -6.948718 |
| Price Hint | 2 |
| Price To Book | 147.28261 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.289 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.95 |
| Regular Market Change Percent | 7.53968 |
| Regular Market Day High | 13.89 |
| Regular Market Day Low | 12.6 |
| Regular Market Day Range | 12.6 - 13.89 |
| Regular Market Open | 12.6 |
| Regular Market Previous Close | 12.6 |
| Regular Market Price | 13.55 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 374,958 |
| Return On Assets | -0.87236 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 18,396,074 |
| Shares Percent Shares Out | 0.0713 |
| Shares Short | 1,311,845 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 1,301,508 |
| Short Name | Elicio Therapeutics, Inc. |
| Short Percent Of Float | 0.1031 |
| Short Ratio | 8.85 |
| Source Interval | 15 |
| State | MA |
| Symbol | ELTX |
| Target High Price | 20.0 |
| Target Low Price | 17.0 |
| Target Mean Price | 18.33333 |
| Target Median Price | 18.0 |
| Total Cash | 18,563,000 |
| Total Cash Per Share | 1.009 |
| Total Debt | 14,512,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.58 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.713975 |
| Two Hundred Day Average Change | 3.8360252 |
| Two Hundred Day Average Change Percent | 0.39489758 |
| Type Disp | Equity |
| Volume | 374,958 |
| Website | https://elicio.com |
| Zip | 2,210 |